The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease
Open accessAbstract
Importance: Clinical subtyping of Parkinson disease at diagnosis is useful in estimating disease course and survival. Severity and rate of progression of neuropathologies are important determinants of clinical Parkinson subtypes. Objective: To provide longitudinal clinical disease-course data and neuropathologic correlation for newly proposed Parkinson disease subtypes. Design, Setting, and Participants: Retrospective cohort study of consecutive patients with autopsy-confirmed Parkinson disease who were regularly seen throughout their disease course by hospital specialists in the United Kingdom and donated their brain at death to the Queen Square Brain Bank between January 2009 and December 2017. Patients with additional neuropathologic diagnoses, monogenic forms of parkinsonism, or insufficiently detailed clinical information were excluded. Based on severity of motor symptoms, rapid eye movement sleep behavior disorder, and autonomic and cognitive function at diagnosis, patients were classified adapting a subtyping classification into mild-motor predominant, intermediate, or diffuse malignant subtypes. Main Outcomes and Measures: Time from diagnosis to disease milestones (recurrent falls, wheelchair dependence, dementia, and care home placement) and death were compared between subtypes, and their risk was estimated using Cox hazard regression models. Severity and distribution of Lewy pathology and Alzheimer disease-related pathology were assessed using staging systems. Results: From a total of 146 patients, 111 patients were included (67 men [60.4%]; mean [SD] age at diagnosis, 62.5 [11.5] years). The diffuse malignant subtype had earlier development of milestones and reduced survival. Cox proportional hazard regression showed an increased adjusted risk of any disease milestone (hazard ratio, 10.90; 95% CI, 5.51-21.58; P < .001) and death (hazard ratio, 3.65; 95% CI, 1.98-6.75; P < .001) in the diffuse malignant group. Age at diagnosis was the only additional variable with statistical significance (adjusted hazard ratio for death, 1.14; 95% CI, 1.11-1.17; P <.001). Staging of Lewy pathology and Alzheimer disease-related pathology did not differ between subtypes, although they showed different rates of progression, and the latter was associated with age at death. Conclusions and Relevance: Parkinson clinical subtypes at diagnosis may estimate disease course and survival, which may be useful in providing a more accurate prognosis in individual patients in clinical practice and helping to stratify subgroups in clinical trials. Different severity and progression of neuropathologies are important determinants of Parkinson subtypes, and age at diagnosis should be included in future subtype classifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“One barrier to the clinical implementation of passive digital biomarkers, however, has been the lack of computing resources for storing and automatically processing and analyzing the large amount of data collected from passive digital tools that continuously monitor behavior over long periods of time.120”
From Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias (2026) · cites this paper as [120]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,310
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
The Parkinson Progression Marker Initiative (PPMI)
MAREK, K. L., Jennings, D. L., Lasch, S., Siderowf, A. D., Tanner, C. M., Simuni, T., Coffey, C. S., Kieburtz, K. D., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,934
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Self-citationClinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression
Fereshtehnejad, S., Zeighami, Y., Dagher, A., & Postuma, R. B. (2017) · Brain · doi:10.1093/brain/awx118 · Cited by 619
Cited by
Sorted by citations
Items 201–300 of 332
Yan, W., Ye, C., Wang, T., Sun, J., Wu, T., & Ma, T. (2020) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc44109.2020.9178266 · Cited by 4
Neuropathological progression of clinical Parkinson disease subtypes
Pablo‐Fernández, E. D., Lees, A. J., Holton, J. L., & Warner, T. T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0197-x · Cited by 4
Self-citationAssociations among blood biomarkers, clinical subtypes, and prognosis in Parkinson’s disease
Oizumi, H., Hasegawa, T., Kawahata, K., Sekimori, T., Totsune, T., Sugimura, Y., Baba, T., Fukunaga, K., & Takeda, A. (2025) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2025.100313 · Cited by 3
Regional neuromelanin reduction in the substantia nigra in different subtype of Parkinson's disease
Shao, X., Jia, J., Li, H., Li, Y., Liu, K., Wang, J., & Jin, L. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107933 · Cited by 3
Arauzo, N. P., Theyer, C., Krismer, F., Djamshidian, A., Poewe, W. H., Horlings, C. G. C., Heim, B., Zamarian, L., & Mahlknecht, P. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1627221 · Cited by 3
Massey, Q., Nihoyannopoulos, L., Zeidman, P., Warner, T. T., Bhatia, K. P., Gandhi, S., & Lambert, C. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01157-y · Cited by 3
Self-citationUntangling the heart–brain connection in Parkinson’s disease: emerging mechanisms and models
Martello, A., & Lionetti, V. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0223 · Cited by 4
Pharmacogenetics in advanced Parkinson’s disease
Kulisevsky, J., Ruiz, P., Outeiro, T. F., Gurevich, T., Klivènyi, P., van Laar, T., Milanov, I. G., Pirker, W., Popescu, B. O., Toft, M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03057-0 · Cited by 3
The challenges with the identification of Parkinson’s disease subtypes
Rigon, L., Popławska-Domaszewicz, K., Metta, V., Fogliano, C. A., Nasi, M. L., Sauerbier, A., Dafsari, H., Leta, V., Falup‐Pecurariu, C., Odin, P., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2611250 · Cited by 5
Ictal SPECT Imaging Findings in Parkinson's Disease with Rapid Eye Movement Sleep Behavior Disorder
Groenewald, K., Warwick, J., Dupont, P. J., Ackerman, J., Amsterdam, O., & Carr, J. A. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14307 · Cited by 3
Petrijan, T., & Menih, M. (2025) · Neurology International · doi:10.3390/neurolint17040051 · Cited by 3
Stefanis, L., & Borghammer, P. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251364115 · Cited by 3
Negida, A., Vohra, H., Lageman, S. K., Mukhopadhyay, N. D., Berman, B. D., Weintraub, D. A., & Barrett, M. J. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108072 · Cited by 3
Molecular Subtyping and Outlier Detection in Human Disease Using the Paraclique Algorithm
Hagan, R. D., & Langston, M. A. (2021) · Algorithms · doi:10.3390/a14020063 · Cited by 3
Perspectives of people living with Parkinson's disease on personalized prediction models
van den Heuvel, L., Knippenberg, M. L., Post, B., Meinders, M. J., Bloem, B. R., & Stiggelbout, A. M. (2022) · Health Expectations · doi:10.1111/hex.13500 · Cited by 3
Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson’s disease
Lima, M. M. S., Targa, A., Lima, G. Z. D. S., Cavarsan, C. F., & Torterolo, P. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.08.008 · Cited by 4
Chronotropic Incompetence in Parkinson’s Disease: A Possible Marker of Severe Disease Phenotype?
Andréasson, M., Nickander, J., Ståhlberg, M., Fedorowski, A., & Svenningsson, P. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230256 · Cited by 3
A Lightweight Parkinson's Disease Diagnostic Method Based on Hand-Drawn Spiral Lines
Wang, L., Liu, H., Chen, X., & Li, Y. (2024) · International Conference on Bioinformatics and Intelligent Computing (BIC) · doi:10.1145/3665689.3665726 · Cited by 3
Pan, C., Tian, Y., Ma, L., Zhou, T., Ouyang, S., & Li, J. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.125506 · Cited by 4
Parkinson's disease: is pharmacotherapy on the move?
Greener, M. (2021) · Prescriber · doi:10.1002/psb.1940 · Cited by 3
Fernández‐Pajarín, G., Sesar, Á., Relova, J. L., Ares, B., Jiménez, I., Gelabert‐González, M., Echabe, E. A., & Castro, A. (2022) · Diagnostics · doi:10.3390/diagnostics12041001 · Cited by 3
Rong, P., & Heidrick, L. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1794169 · Cited by 2
Brain-first and body-first subtypes of Lewy body disease
Borghammer, P., Berge, N. V. D., Berg, D., Takahashi, R., Postuma, R. B., & Horsager, J. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01241-8 · Cited by 3
Sun, Y., Gan, L., Peng, F., Zhou, X., Chen, Q.-S., Liu, F., Tang, Y., Wu, P., Lu, J., Ge, J., et al. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105441 · Cited by 2
Park, D., Lee, S. Y., Kim, J. H., & Kim, H. S. (2023) · Journal Of Big Data · doi:10.1186/s40537-023-00819-z · Cited by 2
G2GNet: A model for video tremor diagnosis in Parkinson’s disease
Qin, J., Liu, Y., Cai, M., Chen, Y. L., Ji, C., & Wang, Z. (2023) · IEEE Smart World Congress (SWC) · doi:10.1109/swc57546.2023.10449314 · Cited by 2
Is rapid eye movement sleep behavior disorder a marker of Parkinson's disease severity?
de Oliveira, P., Ramalho, S. H. R., Martins, B. J. A. F., & Cardoso, F. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107258 · Cited by 2
Morgante, F., Artusi, C. A., Ricciardi, L., Sarchioto, M., Montanaro, E., Edwards, M. J., Lopiano, L., & Zibetti, M. (2025) · European Journal of Neurology · doi:10.1111/ene.70342 · Cited by 2
Grillo, P., Riboldi, G. M., Pisani, A., Kang, U. J., & Fereshtehnejad, S.-M. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261417468 · Cited by 4
Symptomatic vs. Disease-Modifying Therapies
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.011 · Cited by 2
Sommeil et maladies neurodégénératives
Leu‐Semenescu, S. (2022) · Médecine du Sommeil · doi:10.1016/j.msom.2022.10.004 · Cited by 3
Santos‐García, D., Sucarrats, G. M., Medina, H. C., Roca, L. G., & Ríos, L. N. (2021) · Kranion · doi:10.24875/kranion.m21000002 · Cited by 2
Functional Impairment Preceding Parkinson Disease Diagnosis—What’s in a Prodrome?
Bledsoe, I. O., Yu, J., & Shukla, A. W. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4157 · Cited by 2
Progression in Parkinson's DiseasePreprint
Irmady, K., & Przedborski, S. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041641 · Cited by 2
Xu, S., Si, X., Cai, M., Fu, F., Tian, J., Zhang, B., & Liu, X. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1477827 · Cited by 1
Biological frameworks for Parkinson’s disease: the heterogeneity SAAgged
Landolfi, A., Sorrentino, C., Barone, P., & Erro, R. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13049-5 · Cited by 2
Introduction to Gut Microbiota and Its Role in Health and Diseases
Sharma, S., Hussain, M. S., Khan, Y., & Maqbool, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_2 · Cited by 1
Zhu, S., Hong, R., Wu, Z., Bao, Y., Song, Y., Hu, G., Bai, Z., Zhu, F., Liao, Z., Pan, L., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27310 · Cited by 1
Subtyping of Parkinson’s Disease by Longitudinal Trajectories of Levodopa Equivalent Daily Dose
Lee, Y., Baik, K., Park, M., Kang, S. W., & Yoon, S. H. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25099 · Cited by 1
Li, Y., Liu, Y., Lin, Z., Wei, Q., Xiang, J., Zhang, W., Dong, L., Li, F., Zu, J., Cui, G., et al. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150038 · Cited by 1
Arca, V. M., Jurkevičienė, J., Cullinane, P. W., Wrigley, S., Parmera, J. B., Farin, Z., Pimparkar, S., Lim, Y. M., Révész, T., Jaunmuktane, Z., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78257 · Cited by 2
Self-citationDisease Subtypes: The Promise and the Fallacy
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.006 · Cited by 1
Kashihara, K., & Kitayama, M. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8922-21 · Cited by 1
Parkinsonism of uncertain clinical significance (PUCS): A proposed new diagnostic entity
Zitser, J., Brown, E. G., Ostrem, J. L., Tanner, C. M., Rowe, J. B., Nguyen, V. K., Rosen, H. J., Geschwind, M. D., & Bledsoe, I. O. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120696 · Cited by 1
Lin, Y.-F., Fuh, J., & Yang, A. C. (2025) · Neuroimage Reports · doi:10.1016/j.ynirp.2025.100246 · Cited by 1
Dumican, M., Reyers, T., Malczewski, A., & Thijs, Z. (2025) · International Journal of Language & Communication Disorders · doi:10.1111/1460-6984.70124 · Cited by 1
Cognitive impairment and its association with cholinergic dysfunction in Parkinson’s disease
Baba, T., & Takeda, A. (2020) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12417 · Cited by 1
Molecular aspects of neurodegeneration and classification of neurological disorders
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821711-5.00001-2 · Cited by 1
Parkinson’s Disease Gravity Index: A Method by means of Optimal Scaling
Serrano‐Dueñas, M., Campaña, L. A. M., & Luquín, M. R. (2020) · Neurology Research International · doi:10.1155/2020/8871870 · Cited by 1
Containment response to direct heating in pressurized water reactors.
Darwish, S. M. (1991) · Deep Blue (University of Michigan) · Cited by 1
Two distinct trajectories of clinical and neurodegeneration events identified in Parkinson's diseasePreprint
Zhou, C., Wang, L., Cheng, W., Lv, J., Guan, X., Guo, T., Wu, J., Zhang, W., Gao, T., Liu, X., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1880346/v1 · Cited by 1
Baytaş, İ. M. (2023) · doi:10.36227/techrxiv.24078639 · Cited by 1
Neuroimaging and plasma marker evidence for white matter macrostructure loss in Parkinson’s diseasePreprint
Zarkali, A., Hannaway, N., McColgan, P., Heslegrave, A., Veleva, E., Laban, R., Zetterberg, H., Lees, A. J., Fox, N. C., & Weil, R. (2023) · bioRxiv · doi:10.1101/2023.09.22.558937 · Cited by 3
Self-citationUnsupervised Variant Clustering Identifies Genetic Subtypes of DiseasePreprint
Mizikovsky, D., Wray, N. R., Shah, S. H., & Palpant, N. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.01.662666 · Cited by 1
Reply to ‘Neuropathological progression of clinical Parkinson disease subtypes’
Espay, A. J., & Marras, C. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0198-9
Cognitive and Emotional Symptoms in Patients with Parkinson’s Disease
Argüelles, J. L. (2019) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2019.05.000607
Joppe, K. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8016
Clinical Trials for Gait Disorders in Parkinson’s Disease
Košutzká, Z., Fietzek, U. M., & Valkovič, P. (2020) · Neuromethods · doi:10.1007/978-1-0716-0912-5_6
Two Types of Parkinson's Disease Pathologies: Body-First Versus Brain-First
Hurley, D. (2020) · Neurology Today · doi:10.1097/01.nt.0000723776.83802.fc
Parkinson’s disease subtypes: literature review
Diachenko, P. Y., & Moskovko, G. S. (2020) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2020-24(3)-23
The Hypothesis That Refuses to Die
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.012
Parkinson’s Disease and Eating and Weight Disorders
Cuzzolaro, M., & Melchionda, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-81174-7_31
Plouvier, A. O. A., & Post, B. (2021) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2707-2_11
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.020
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.013
Disease “Redefinition”: A Tough Pill to Swallow
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.005
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.008
The Shaky Six and the “Second Reality”
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.003
Predictions for the 2020s and Beyond
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.017
The Scientific and Lay Narratives
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.014
Note Added at Press Time – Reviving LOF
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.019
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.001
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.015
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.018
The Moonshot: Population-Based Studies of Aging
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.016
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.002
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.010
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.004
Biomarkers: The Promise and the Fallacy
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.009
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.007
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202.021
Histoire naturelle de la maladie de Parkinson idiopathique
Houéto, J. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76331-1.00019-7 · Cited by 1
ФУНКЦІОНАЛЬНИЙ СТАН ВЕГЕТАТИВНОЇ НЕРВОВОЇ СИСТЕМИ У ХВОРИХ НА ХВОРОБУ ПАРКІНСОНА
Хубетова, И. В. (2022) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2022.v.i1.13007
Parkinson’s Disease and Atypical Parkinsonian Syndromes
Ridgeway‐Diaz, J. G., & Marsh, L. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197574317.003.0017
Neuroophthalmic abnormalities in supranuclear palsy
Венгер, Л. В., & Хубетова, И. В. (2022) · Oftalmologicheskii Zhurnal · doi:10.31288/oftalmolzh202253741
Foslevodopa-Foscarbidopa (Vyalev)
CADTH (2023) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2023.737
Massey, Q., Nihoyannopoulos, L., Zeidman, P., Warner, T. T., Bhatia, K. P., Gandhi, S., & Lambert, C. (2023) · medRxiv · doi:10.1101/2023.12.12.23299891
Self-citationBanerjee, L. V., Pasquini, J., Henderson, R., Pavese, N., & Anderson, K. N. (2024) · medRxiv · doi:10.1101/2024.03.18.24304459
Geut, A. J. (2024) · doi:10.5463/thesis.484
Massey, Q., Nihoyannopoulos, L., Zeidman, P., Warner, T. T., Bhatia, K. P., Gandhi, S., & Lambert, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865047
Self-citationFrucht, S. J., & Termsarasab, P. (2024) · Springer eBooks · doi:10.1007/978-3-031-52573-5_2
Subtypen der Parkinson-Krankheit
Ebersbach, G. (2024) · Neurologie up2date · doi:10.1055/a-2127-2547
Wolters, E. C. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.013
Faustini, G., Mazzocco, M. T., Comelli, A., Brugnoli, A., Benfante, V., Brembati, V., Longhena, F., Gennari, M. M., Coliva, A., Magnino, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6502918/v1
Subtypen der Parkinson-Krankheit
Ebersbach, G. (2025) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2521-3214
Deciphering the Interplay: DNA Methylation Dynamics in Aging and Neurodegenerative Diseases
Lee, Y., & Lee, S.-M. (2025) · RNA technologies · doi:10.1007/978-3-031-91072-2_2
Jin, Y., & Ge, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1579561
Signes moteurs et critères diagnostiques
Carey, G., & Defebvre, L. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78712-6.00006-3
Metadata
- Authors
- De Pablo-Fernández, E., Lees, A. J., Holton, J. L., & Warner, T. T.
- Affiliations
- Reta Lila Weston Institute of Neurological Studies, University College London Queen Square Institute of Neurology, London, England
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Warner, Thomas T.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-04-01
- Volume
- 76
- Issue
- 4
- Pages
- 470
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC6459129
- OpenAlex
- W2909700430
- Cited by
- 332
- References
- 31
- Citations by year
- 2026: 23 · 2025: 53 · 2024: 45 · 2023: 42 · 2022: 46 · 2021: 39 · 2020: 63 · 2019: 20
- FWCI
- 28.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Medical Research Council (MR/L023784/2, MR/L023784/1)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, clinical subtypes, prognosis, disease progression, survival, Lewy body pathology, rapid eye movement sleep behavior disorder, dementia, wheelchair dependence, nursing home admission, age at death, autonomic dysfunction, cognitive function, brain donation
- MeSH terms
- Aged, Autonomic Nervous System Diseases, Autopsy, Brain, Female, Humans, Male, Middle Aged, Parkinson Disease, Prognosis, Retrospective Studies, Severity of Illness Index, Survival Rate, Proportional Hazards Models, Lewy Bodies, Neurofibrillary Tangles, Age of Onset, Disease Progression, REM Sleep Behavior Disorder, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
